INDEPENDENT LIMITED ASSURANCE STATEMENT

To: The Stakeholders of AstraZeneca Plc

Introduction and objectives of work

Bureau Veritas UK Limited (“Bureau Veritas”) has been engaged by AstraZeneca Plc (“AstraZeneca”) to provide limited assurance over sustainability activities reported in the AstraZeneca Annual Report and form 20-
F Information 2021 (the “Report”). This Assurance Statement applies to the related information included within the scope of work described below.

Scope of work

Subject to the below exclusions, the scope of our work was limited assurance over select information included within the following sections of the ‘Report’ for the period 1st of January to the 31st of December 2021 (the “Selected Information”):

- AstraZeneca at a Glance: all text and data under Commitment to Society;
- Our prioritised Initiatives: all text and data under Sustainability and data pertaining to the Sustainability Scorecard Performance;
- Business Review: all text under Our sustainability approach;
- Bioethics: all text and data under Clinical trial transparency, Research use of human biological samples and Animal research;
- Sales and Marketing: all text and data under Healthcare in Low- and Middle-Income Countries (LMICs), Responsible sales and marketing, Anti-bribery and anti-corruption;
- Operations: all text and data under Responsible Supply Chain;
- Be A Great Place to Work: all text and data under the Performance Indicators section on Contribution to Enterprise;
- Human Rights: all text and data
- Employee relations: all text and data
- Workplace safety and health: all text and data
- Sustainability: all text and data, including under Driving the sustainability agenda;
- Access to healthcare: all text and data, including Equitable access, Diversity in clinical trials, Rare diseases, Affordability and pricing, Health system resilience, Healthy Heart Africa Programme, Young health programme;
- Community Investment: all text and data
- Product Donation Programme: all text and data
- Environmental Protection: all text and data, including Ambition Zero Carbon, Near-term targets, Long-term targets, Product sustainability, Natural resources, Water stewardship, Green labs, Building a framework for circularity;
- Ethics and transparency: all text and data under Achievements in 2021; and
- Sustainability Supplementary Information: all text and data under Greenhouse Gas (GHG) reporting, including restated 2019 and 2020 figures to include Alexion Pharmaceuticals data in the Global GHG emissions data table;
- Taskforce on Climate-related Financial Disclosures: all text and data.
Reporting Criteria

The Selected Information has been prepared in accordance with internal definitions set by AstraZeneca in their sustainability strategy and the Global Safety, Health & Environment Performance Reporting Procedure. The definitions for AstraZeneca’s GHG reporting are aligned with the Greenhouse Gas Protocol Corporate Accounting and Reporting Standard (revised edition), as set out in the “Greenhouse gas (GHG) reporting” section of the Report.

Responsibilities

The preparation and presentation of the Selected Information in the Report is the sole responsibility of the management of AstraZeneca.

Bureau Veritas was not involved in the drafting of the Report. Our responsibilities were to:

- Obtain limited assurance about whether the Selected Information has been appropriately and accurately prepared;
- Form an independent conclusion based on the assurance procedures performed and evidence obtained; and
- Report our conclusions to the Directors of AstraZeneca.

Assessment Standard

Our work was performed to a ‘limited’ level of assurance in accordance with International Standard on Assurance Engagements (ISAE) 3000 (Revised), Assurance Engagements Other than Audits or Reviews of Historical Financial Information, and in accordance with International Standard on Assurance Engagements 3410 - ‘Assurance Engagements on Greenhouse Gas Statements’ (‘ISAE 3410’), issued by the International Auditing and Assurance Standards Board.

Limitations and Exclusions

Excluded from the scope of our work is the verification of information relating to:

- Any progress reported against restated 2015 baselines;
- The statement, “Renewable power implemented by 2020 at all sites with a 2% premium.”;
- Data for the Healthy Lung programme for 2021 which feeds into the number of “healthcare workers trained since 2010” and the reported millions of “people reached through Access to Healthcare programmes”;
- Activities outside the defined verification period;
- Positional statements (expressions of opinion, belief, aim or future intention by AstraZeneca) and statements of future commitment;
- Financial data taken from the Report which are audited by an external financial auditor, including but not limited to any statements relating to production, tax, sales, and financial investments; and
- Other information included in the Report other than scope defined above.
This limited assurance engagement relies on a risk-based selected sample of sustainability data and the associated limitations that this entails. The reliability of the reported data is dependent on the accuracy of data collection and monitoring arrangements at market/site level, and it should be noted that not all the Selected Information was sampled at site level as part of this assurance. This independent statement should not be relied upon to detect all errors, omissions or misstatements that may exist.

Summary of work performed
As part of its independent verification, Bureau Veritas undertook the following activities:

1. Conducted interviews with relevant personnel of AstraZeneca at both Corporate and site levels;
2. Carried out four virtual site audits, at the following sites: Cambridge Central – UK, IPR Pharmaceuticals – Puerto Rico, Newark – US, and Moscow – Russia. Sites were selected through a risk-based approach following discussion with Bureau Veritas and AstraZeneca, with consideration of contribution to assured data, geographical distribution and type of operations;
3. Reviewed the data collection and consolidation processes used to compile the Selected Information, including assessing assumptions made, the data scope, and reporting boundaries;
4. Reviewed documentary evidence provided by AstraZeneca;
5. Reperformed a selection of aggregation calculations of the Selected Information;
6. Agreed a selection of the Selected Information to the corresponding source documentation; and
7. Assessed the disclosure and presentation of the Selected Information to ensure consistency with assured information.

The scope of a limited assurance engagement is substantially less than for reasonable assurance both in terms of the risk assessment procedures and in performing the procedures to address the identified risks.

Conclusion
On the basis of our methodology and the activities and limitations described above, nothing has come to our attention to indicate that the Selected Information is not fairly stated in all material respects. However, the following, which are not considered to have resulted in any material misstatement of the data, should be noted:

- The electricity consumption linked to electric and plug-in hybrid vehicles of the leased fleet falling within operational control of AstraZeneca has not been captured under scope 2 emissions and has instead been captured entirely under scope 1 emissions.
- GHG emissions are calculated for CO₂, not CO₂e for the following: Scope 1 fleet emissions.

Statement of Independence, Integrity and Competence
Bureau Veritas is an independent professional services company that specialises in quality, environmental, health, safety and social accountability with over 190 years’ history. Its assurance team has extensive experience in conducting verification over environmental, social, ethical and health and safety information, systems and processes.

Bureau Veritas operates a certified¹ Quality Management System which complies with the requirements of ISO 9001:2015 and accordingly maintains a comprehensive system of quality control including documented policies

¹ Certificate available on request
and procedures regarding compliance with ethical requirements, professional standards and applicable legal and regulatory requirements.

Bureau Veritas has implemented and applies a Code of Ethics, which meets the requirements of the International Federation of Inspections Agencies (IFIA)² across the business to ensure that its employees maintain integrity, objectivity, professional competence and due care, confidentiality, professional behaviour and high ethical standards in their day-to-day business activities.

Bureau Veritas UK Limited
London
9 February 2022
REF: 12276910_AR_v1.0

² International Federation of Inspection Agencies – Compliance Code – Third Edition